The stock is a binary catalyst play on the Phase 3 LUCIDITY topline data readout for avexitide in PBH, expected in late August or early September 2026. Positive data could unlock a first-in-class approval opportunity in a $160K-patient U.S. market with no approved therapies, while negative data would leave the company with a pipeline still in early stages and a cash runway into 2028. Traders should position for volatility around the readout date.
Price Chart
Executive Summary
Amylyx Pharmaceuticals reported Q2 2026 financial results with a net loss of $43.4M ($0.39/share), missing the consensus EPS estimate of -$0.36 by 9%. The pre-revenue biotech's cash burn continues, with cash decreasing to $250.8M from $279.8M at Q1 end, though the company maintains cash runway into 2028. The key catalyst is the upcoming Phase 3 LUCIDITY topline data readout for avexitide in post-bariatric hypoglycemia, expected in late August or early September 2026, which will determine the stock's near-term direction.
Key Financial Metrics
Key Facts
- Net loss of $43.4M ($0.39/share) for Q2 2026 vs $41.4M ($0.46/share) in Q2 2025
- EPS of -$0.39 missed consensus estimate of -$0.36 (9% miss)
- Cash, cash equivalents, and short-term investments were $250.8M at June 30, 2026, down from $279.8M at March 31, 2026
- Cash runway expected to fund operations into 2028
- Last participant completed final study visit in Phase 3 LUCIDITY trial of avexitide; topline data anticipated in late August or early September 2026
- R&D expenses decreased to $23.8M from $27.2M YoY; SG&A expenses increased to $21.9M from $15.6M YoY
Financial Impact
Net loss of $43.4M in Q2 2026, with cash burn of ~$29M from Q1 2026
Risk Factors
- Phase 3 LUCIDITY trial failure would remove the near-term value driver and leave the company with only early-stage pipeline assets
- Cash burn rate of ~$29M/quarter with no revenue; runway into 2028 provides buffer but limits strategic flexibility
- SG&A expenses increased 40% YoY to $21.9M, driven by legal and pre-commercial costs, without any approved product revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336670 |
| Document: amlx-20260806.htm | 0001193125-26-336670 |
| Document: 0001193125-26-336670-index-headers.html | 0001193125-26-336670 |
| Document: 0001193125-26-336670-index.html | 0001193125-26-336670 |
| Document: 0001193125-26-336670.txt | 0001193125-26-336670 |
| 8-K Data (Synthetic) | 0001193125-26-336670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 144 | $28.04 | awaiting T+20 | — | $27.09 (−3.39%) |
Sep 14, 2026 6w ago | Insider Cluster | $33.15 $26.85 | ▼ −19.00% | ▼ −21.73% | $27.09 (−18.28%) |
Sep 11, 2026 6w ago | 144 | $33.64 $27.48 | ▼ −18.31% | ▼ −20.57% | $27.09 (−19.47%) |
Aug 18, 2026 9w ago | 8-K | $35.11 $33.05 | ▼ −5.87% | ▼ −4.88% | $27.09 (−22.84%) |
Aug 15, 2026 10w ago | Institutional Cluster | $21.43 $33.15 | ▲ +54.69% | ▲ +56.67% | $27.09 (+26.41%) |
Aug 6, 2026 11w ago | 8-K | $24.19 $33.96 | ▲ +40.39% | ▲ +39.79% | $27.09 (+11.99%) |
Jun 11, 2026 19w ago | Institutional Cluster | $13.91 $18.38 | ▲ +32.14% | ▲ +30.24% | $27.09 (+94.75%) |
Apr 23, 2026 26w ago | DEFA14A | $17.32 $13.61 | ▼ −21.42% | ▼ −26.05% | $27.09 (+56.41%) |
Mar 2, 2026 34w ago | Insider Cluster | $15.30 $12.76 | ▼ −16.60% | ▼ −8.66% | $27.09 (+77.06%) |
Feb 23, 2026 35w ago | Insider Cluster | $13.90 $13.53 | ▲ +2.66% | ▼ −1.28% | $27.09 (−94.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers